A couple of weeks ago I was invited to present at the 2009 Nebraska Research and Innovation Conference. The theme of my talk was “The Case for Improving Existing Drugs”.
There are several factors driving people to the 505(b)(2) development pathway, a couple of which are:
Generic cliff. By about 2017 there will be very few remaining [...]
